Sol Sherry Lecture in Thrombosis
1998; Lippincott Williams & Wilkins; Volume: 18; Issue: 4 Linguagem: Inglês
10.1161/01.atv.18.4.514
ISSN1524-4636
Autores Tópico(s)Protease and Inhibitor Mechanisms
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 18, No. 4Sol Sherry Lecture in Thrombosis Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUBSol Sherry Lecture in Thrombosis How Thrombin ‘Talks’ to Cells Molecular Mechanisms and Roles In Vivo Shaun R. Coughlin Shaun R. CoughlinShaun R. Coughlin From the Cardiovascular Research Institute, Departments of Medicine and Cellular and Molecular Pharmacology, University of California at San Francisco. Search for more papers by this author Originally published1 Apr 1998https://doi.org/10.1161/01.ATV.18.4.514Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18:514–518This article is a summary of the Sol Sherry Lecture of the Council on Arteriosclerosis, Thrombosis, and Vascular Biology, which was presented at the 70th Scientific Sessions of the American Heart Association in November 1997. It highlights work from our laboratory addressing the molecular mechanisms by which the coagulation protease thrombin elicits cellular responses, notes some of the novel issues that protease signaling raises, and cites recent work on the role of thrombin signaling in vivo.Thrombin is a multifunctional serine protease. In adult animals, active thrombin is generated in the context of vascular injury when activation of the coagulation cascade triggers conversion of the circulating zymogen prothrombin to active protease. Thrombin generation may also be important in other contexts, as will be shown below.Several of thrombin’s functions involve cleavage of circulating protein substrates, eg, conversion of fibrinogen to fibrin monomer or activation of protein C. However, thrombin also has important actions on cells. It is the most potent activator of platelets.1 It causes endothelial cells to deliver the leukocyte adhesion molecule P-selectin to their surfaces,2 to secrete von Willebrand factor,2 and to elaborate growth factors and cytokines.34 It is also a mitogen for fibroblasts and vascular smooth muscle cells.5 Such cellular actions of thrombin raised several important questions. How does thrombin, a protease, act like a hormone to control cellular behaviors? And what are the roles of thrombin-regulated cellular events in vivo?Thrombin’s actions on platelets are of particular interest. Arterial thrombosis underlies most cases of unstable angina and myocardial infarction. Studies in animal models and clinical trials suggest that these events are both platelet dependent and thrombin dependent, but the relative contributions of and interactions between thrombin-induced platelet activation and fibrin formation in acute coronary syndromes are not known. By elucidating the mechanisms whereby thrombin activates platelets, we thus hoped to uncover new signaling mechanisms, provide tools for dissecting the pathophysiology of arterial thrombosis, and possibly, reveal new targets for therapeutic development.We utilized an expression cloning strategy to identify a thrombin receptor.6 This receptor, now known as protease-activated receptor 1 (PAR1), is a member of the seven transmembrane domain G protein–coupled receptor family67 but is activated by a novel mechanism.Mechanism of PAR ActivationPAR1’s amino-terminal exodomain contained the putative thrombin cleavage site LDPR/S, which resembled a known thrombin cleavage site in protein C. Carboxyl to this site was the sequence DKYEPFWEDEE, which resembled a sequence in the thrombin inhibitor hirudin known to interact with thrombin’s fibrinogen-binding exosite. These observations suggested that thrombin might recognize PAR1’s amino-terminal exodomain and cleave the peptide bond between receptor residues R41 and S42 (the Figure).6 Mutation of the R41/S42 cleavage site to an “uncleavable” R/P site rendered the receptor unactivatable by thrombin.6 Replacement of the thrombin cleavage recognition sequence LDPR/S with DDDDK/S, the recognition site for enteropeptidase, switched receptor specificity; cells expressing this construct responded to enteropeptidase but not to thrombin.89 Thus, mutation studies suggested that cleavage of the R41/S42 peptide bond was both necessary and sufficient for receptor activation by thrombin.Biochemical studies supported this notion. Thrombin cleaved the soluble recombinant PAR1 amino-terminal exodomain efficiently and specifically at the R41/S42 peptide bond.10 Cleavage of PAR1 on intact cells was demonstrated by using antibodies to the receptor’s activation peptide (the fragment cleaved from the receptor by thrombin) versus antibodies to receptor domains retained after cleavage.11 Mutation of the R41/S42 site to R/P prevented receptor cleavage in these studies. The rates of receptor cleavage and second-messenger generation were well correlated.11PAR1 recognition by thrombin indeed appears to be mediated by two short sequences within PAR1’s amino-terminal exodomain. X-ray crystallographic studies of thrombin cocrystallized with receptor peptides confirmed that PAR1 residues 39 to 41 (LDPR) can “dock” in thrombin’s active center and that residues 50 to 55 (DKYEPF) can bind thrombin’s fibrinogen-binding exosite.12 The receptor region containing these sequences appears to be sufficient to account for thrombin-receptor interaction. It was cleaved with similar kinetics, whether displayed on the cell surface in its normal context in PAR1 or on an irrelevant membrane “tether.”10 The importance of the DKYEPF interaction with thrombin has been demonstrated in functional studies with mutant receptors and in biochemical studies with receptor-based peptides.81314 Mutation studies identified receptor residues Y52, E53, and F55 as key for interaction with thrombin and suggested that they might dock with thrombin’s anion-binding exosite in a manner similar to residues F56, E57, and I59 of the leech anticoagulant hirudin815 (the Figure). This analogy was supported in the x-ray crystallographic studies mentioned above.12 Occupancy of thrombin’s fibrinogen-binding exosite by the DKYEPF sequence was associated with a conformational change in thrombin’s active center,1213 and the presence of the DKYEPF sequence in model peptide substrates was associated with both a lower Km and higher kcat.810 Studies with mutant receptors suggest that the binding of the DKYEPF sequence to thrombin may induce a conformational change in thrombin’s active center that is important for thrombin’s ability to bind and cleave the LDPR/S sequence.10 Thus, thrombin and PAR1 have evolved a rather intimate and cooperative protease-substrate relationship to enhance the efficiency and specificity of PAR1 cleavage at the R41/S42 peptide bond.How might proteolysis within PAR1’s amino-terminal extension cause transmembrane signaling? The synthetic peptide SFLLRN, which mimics the new amino terminus created when thrombin cleaves PAR1 (S42FLLRN47), was a PAR1 agonist and bypassed the requirement for receptor proteolysis.61617 This key observation suggested two possible models.618 The first was the “tethered-ligand” hypothesis. In this model, the new amino-terminus SFLLRN was unmasked by receptor proteolysis functions as a tethered peptide agonist, docking intramolecularly with the body of the receptor to effect signaling (the Figure). The second was the “release-from-inhibition” hypothesis. In this model, PAR1 is tonically constrained in an off state by the amino-terminal exodomain, and receptor cleavage or competition by exogenous peptide releases the receptor from this tonic inhibition. This second model was refuted by the observation that a mutant PAR1 lacking an amino-terminal exodomain was not constitutively active, as would be predicted by the release-from-inhibition hypothesis. Moreover, this deletion mutant responded to the SFLLRN synthetic peptide like the wild-type receptor, consistent with the tethered ligand hypothesis. Other experiments confirmed that intramolecular as opposed to intermolecular ligand binding is the predominant mode of thrombin receptor activation.18The thrombin receptor can thus be viewed as a peptide receptor that contains its own agonist. This “agonist-peptide” or tethered-ligand domain is kept “silent” in the naive receptor, to be unveiled only by receptor cleavage. How is this accomplished? Structure-activity studies with synthetic peptides representing the tethered-ligand domain revealed that adding residues at the amino terminus of the SFLLRN peptide or removing its N-terminal protonated amino group ablated its agonist activity.161719 Cleavage of the R41/S42 peptide bond in PAR1 would both remove sequence amino terminal to S42 and create the critical protonated amino group at the tethered ligand’s amino terminus. These actions presumably constitute the proteolytic “switch” that allows the tethered ligand to express activity.Where within PAR1 does the tethered ligand dock? Available data suggest that PAR1’s tethered ligand is recognized at least in part by the receptor’s extracellular “face,” in particular a section of PAR1’s second extracellular loop and a region just outside PAR1’s first transmembrane domain.2021 Interestingly, mutations that have caused constitutive activation of PAR1 were found in these same regions,22 consistent with the notion that alteration of these extracellular structures by ligand binding might effect transmembrane signaling. As for other G protein–coupled receptors, the details of how agonist binding effects movement of the receptor’s transmembrane domains and G protein activation are unknown.How Does a Cell Accommodate the Irreversibility of PAR1’s Activation Mechanism?Classically, G protein–coupled receptor signaling is terminated by dissociation from ligand or by phosphorylation of activated receptor by G protein–coupled receptor kinases. The phosphorylated receptor then binds arrestin, which prevents the receptor from signaling by blocking its interaction with G proteins. After their initial uncoupling, most activated G protein–coupled receptors are subsequently internalized into endosomes, where it is thought that they dissociate from their ligands, become dephosphorylated, and then return to the cell surface in a state capable of responding again to ligand.23The proteolytic mechanism by which PAR1’s tethered ligand is unmasked and its tethered status make for an irreversible activation mechanism, in contrast to the reversible agonist binding that mediates activation of classic G protein–coupled receptors. This begs the question of how desensitization and resensitization are accomplished for an irreversibly activated receptor.Like other activated G protein–coupled receptors, activated PAR1 becomes rapidly phosphorylated, and PAR1 phosphorylation appears to promote its uncoupling from downstream signaling pathways.1124 In fibroblasts and endothelial cells, PAR1 also undergoes rapid activation-triggered internalization.25262728 However, unlike classic G protein–coupled receptors, which sequester and recycle, activated PAR1 is sorted predominantly to lysosomes.252729 If PAR1 were to recycle like classic G protein–coupled receptors, would this alter its signaling behavior? Is PAR1’s distinctive trafficking pattern—the sorting of activated and internalized PAR1 to lysosomes—critical for termination of PAR1 signaling? Studies to address these questions are ongoing. If disposal of PAR1 is indeed a solution to the irreversibility of its activation mechanism, this would represent an interesting connection between trafficking and signaling and would raise the possibility that naturally occurring mutations that defeat PAR1’s sorting to lysosomes might result in gain of function in signaling.The finding that activated PAR1 is internalized and degraded begs the question of how a cell maintains or regains the ability to respond to thrombin. In fibroblasts and endothelial cells, PAR1 resides both on the plasma membrane and in an intracellular compartment. Intracellular PAR1 is protected from cleavage by thrombin. PAR1 appears to cycle tonically between these two compartments, and delivery of naive PAR1 to the cell surface is correlated with the recovery of sensitivity to thrombin.2729 Studies with PAR1 mutants have suggested that agonist-triggered internalization requires receptor phosphorylation, but tonic internalization does not. Determining the mechanism by which tonic internalization and recycling of naive thrombin receptors occurs and the relative importance of this pathway for maintaining sensitivity to thrombin remain a challenge.Role of PAR1 In VivoWhich of thrombin’s known cellular actions are mediated by PAR1, and what is the importance of these actions in vivo? Toward answering these questions, a PAR1-deficient mouse was generated. This mouse strain revealed an unexpected role for PAR1 in development and provided definitive evidence for a second thrombin receptor on mouse platelets and for tissue-specific roles for distinct thrombin receptors.3031Mouse embryos lacking PAR1 developed normally through the first 8.5 days (E8.5). By E9.0, delayed development was generally evident, and by E9.5, embryos lacking PAR1 were markedly smaller and less developed than their wild-type or heterozygous littermates. Half or more of PAR1-deficient embryos die at this time. Thus, PAR1 is important during a critical “window” between E8.5 and E9.5 of mouse embryonic development. What is the mechanism of embryonic loss in PAR1 deficiency? Organogenesis, development of the vasculature and yolk sac circulation, early hematopoiesis, and other important events occur between E8.5 and E9.5. At E9.5, PAR1 is expressed by the endocardium and endothelium, a circulating hematopoietic precursor of unknown identity, in the developing nervous system, and in mesenchymal cells. A preliminary histological examination of PAR1-deficient embryos at E9.5 revealed general developmental delay without any characteristic single abnormality. On the basis of the relatively high level of PAR1 mRNA expression in the endocardium, endothelium, and hematopoietic cells at E9.5, it is tempting to postulate a role for PAR1 in vascular development or hematopoiesis. Delayed maturation of the yolk sac circulation was noted in some PAR1-deficient embryos but was associated with general developmental delay. It is thus not possible to say whether this defect is primary or secondary. It is interesting to note that platelets are not yet present at E9.532 and indeed, are not required for normal development throughout this period.33 Moreover, there is no defect in hemostasis in PAR1-deficient adult mice (see below). It is thus likely that the mechanism of failed development in PAR1-deficient embryos does not involve hemostasis in the usual sense. It is also interesting to note that the factor V knockout mouse displays an embryonic phenotype similar to that of PAR1.34 This is consistent with the notion that factor V and PAR1 may act in the same developmental process. Factor V is necessary for normal thrombin generation; thus, these observations raise the exciting possibility that the “coagulation cascade” is playing an important role in embryonic development that is distinct from its role in hemostasis. Understanding the cellular basis of the defective development of PAR1-deficient embryos remains an important goal.Despite the developmental phenotype described above, a significant fraction of PAR1-deficient embryos survived to term, were born without apparent defects, and developed normally postnatally. There was no evidence of spontaneous bleeding, and tail bleeding times in these mice were indistinguishable from those of the wild type. Moreover, aggregation, secretion, and calcium mobilization to thrombin were identical in wild-type and PAR1-deficient platelets. PAR1-activating peptides did not activate mouse platelets303536 but did activate cells transfected with mouse PAR1 cDNA.30 These data strongly suggest that PAR1 plays only a minor role in mouse platelet activation and provide definitive evidence for a second thrombin receptor in mouse platelets (see below). In contrast to mouse platelets, all known thrombin responses sought were ablated in fibroblasts derived from PAR1-deficient mice—clear evidence for tissue-specific roles for distinct thrombin receptors. Examination of thrombin signaling in other cell types derived from these mice is ongoing.What is the identity of the second thrombin receptor in mouse platelets? We recently identified a candidate designated protease-activated receptor 3 (PAR3).37 PAR3 displayed the structural features of a thrombin receptor with an obvious “hirudin-like domain” for thrombin recognition. It was specifically cleaved by thrombin at a site analogous to that in PAR1 and mediated thrombin signaling when expressed heterologously in Xenopus oocytes or Cos7 cells. In situ hybridization revealed it to be highly expressed in mouse megakaryocytes, with little signal seen in other cell types. Antibodies to PAR3 inhibited mouse platelet activation by thrombin, but this inhibition was overcome at high thrombin concentrations.38 PAR3 thus appears to be an important mediator of thrombin signaling in mouse platelets, but we certainly cannot exclude an additional thrombin receptor in mouse platelets. Analysis of PAR3-knockout mice will provide a definitive answer.The apparent species differences in thrombin receptor utilization by mouse and human platelets may be summarized as follows. Human platelets express PAR1 and are activated by the PAR1 agonist SFLLRN.616173940 PAR1 antibodies inhibit human platelet activation by thrombin, but as for PAR3 in mouse platelets, this inhibition is overcome at high thrombin concentrations. Thus, PAR1 seems to be an important contributor to human platelet activation by thrombin but plays little if any role in mouse platelet activation. As discussed above, PAR3 seems to be important for mouse platelet activation; its role in humans is unknown.In conclusion, characterization of PAR1 provided one answer to the question of how a protease can function as a hormone to activate cells. PAR1 is prototypical of a small family of PARs. These now number three: PAR1 and PAR3 as discussed above, and PAR2,41 which has not been discussed here because it is activated not by thrombin but by trypsin and tryptase.4142 Time will tell how large this family becomes and the extent of its repertoire in mediating protease signaling. The irreversibility of the PARs’ activation mechanism is revealing new links between receptor signaling and intracellular trafficking. Last, PARs provide an important tool for dissecting the roles of protease signaling in physiology and pathophysiology. Whether PAR antagonists will play a role in antiplatelet therapy or find more novel applications remains to be seen.Download figureDownload PowerPoint Figure 1. Protease-activated receptors (PARS): cleavage site and tethered-ligand sequences and mechanism of activation. A, Amino acid sequences relevant to cleavage and activation of PAR1, 2, and 3 are shown. Thrombin recognizes PAR1 via the LDPR and DKYEPF sequences and cleaves the R41/S42 peptide bond (/). This serves to “unmask” the tethered-ligand sequence SFLLRN. The importance of the “hirudin-like” sequences found in thrombin receptors PAR1 and PAR3 (underlined) for receptor recognition by thrombin is discussed in the text. PAR2, which is activated by trypsin and tryptase but not thrombin, does not have such a sequence. B, Cleavage of the R41/S42 peptide bond by thrombin (green sphere) unmasks a new tethered ligand that binds intramolecularly to the receptor to effect transmembrane signaling. The thrombin receptor can thus be viewed as a peptide receptor that carries its own ligand. This ligand remains “silent” until revealed by receptor cleavage.This work was supported by NIH grants HL44907, DK50267, and HL59202 and the Daiichi Research Center at UCSF (to S.R.C.). Thanks are due to my many colleagues who contributed to this work.FootnotesCorrespondence to Shaun R. Coughlin, Cardiovascular Research Institute, Departments of Medicine and Cellular and Molecular Pharmacology, University of California at San Francisco, 505 Parnassus Ave, San Francisco, CA 94143-0130. E-mail shaun—[email protected] References 1 Davey M, Luscher E. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature.1967; 216:857–858.CrossrefMedlineGoogle Scholar2 Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial vWF is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem.1989; 264:7768–7771.CrossrefMedlineGoogle Scholar3 Daniel TO, Gibbs VC, Milfay DF, Garavoy M, Williams LT. Thrombin stimulates c-sis gene expression in microvascular endothelial cells. J Biol Chem.1986; 261:9579–9582.CrossrefMedlineGoogle Scholar4 Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol.1994; 144:975–985.MedlineGoogle Scholar5 McNamara CA, Sarembok IJ, Gimple LW, Fenton JW II, Coughlin SR, Owens GK. Thrombin stimulation of smooth muscle cell proliferation is mediated by a proteolytic, receptor-mediated mechanism. J Clin Invest.1992; 91:94–98.Google Scholar6 Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell.1991; 64:1057–1068.CrossrefMedlineGoogle Scholar7 Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pagers G, Pavirani A, Lecocq JP, Pouyssegur J, Van Obberghen-Schilling E. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett.1991; 288:123–128.CrossrefMedlineGoogle Scholar8 Vu T-KH, Wheaton VI, Hung DT, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature.1991; 353:674–677.CrossrefMedlineGoogle Scholar9 Hung DT, Wong YH, Vu T-KH, Coughlin SR. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate both phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem.1992; 353:20831–20834.Google Scholar10 Ishii K, Gerszten R, Zheng Y-W, Turck CW, Coughlin SR. Determinants of thrombin receptor cleavage: receptor domains involved, specificity, and role of the P3 aspartate. J Biol Chem.1995; 270:16435–16440.CrossrefMedlineGoogle Scholar11 Ishii K, Hein L, Kobilka B, Coughlin SR. Kinetics of thrombin receptor cleavage on intact cells: relation to signaling. J Biol Chem.1993; 268:9780–9786.CrossrefMedlineGoogle Scholar12 Mathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CW, Coughlin SR, Fenton JN. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry.1994; 33:3266–3279.CrossrefMedlineGoogle Scholar13 Liu L, Vu T-KH, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem.1991; 266:16977–16980.CrossrefMedlineGoogle Scholar14 Hung DT, Vu T-KH, Wheaton VI, Charo IF, Nelken NA, Esmon CT, Coughlin SR. “Mirror image” antagonists of thrombin-induced platelet activation based on thrombin receptor structure. J Clin Invest.1992; 89:444–450.CrossrefMedlineGoogle Scholar15 Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JD. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science.1990; 249:277–280.CrossrefMedlineGoogle Scholar16 Vassallo RRJ, Kieber-Emmons T, Cichowski K, Brass LF. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem.1992; 267:6081–6085.CrossrefMedlineGoogle Scholar17 Scarborough RM, Naughton M, Teng W, Hung DT, Rose J, Vu T-KH, Wheaton VI, Turck CW, Coughlin SR. Tethered ligand agonist peptides: structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem.1992; 267:13146–13149.CrossrefMedlineGoogle Scholar18 Chen J, Ishii M, Wang L, Ishii K, Coughlin SR. Thrombin receptor activation: confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. J Biol Chem.1994; 269:16041–16045.CrossrefMedlineGoogle Scholar19 Coller BS, Ward P, Ceruso M, Scudder LE, Springer K, Kutok J, Prestwich GD. Thrombin receptor activating peptides: importance of the N-terminal serine and its ionization state as judged by pH dependence, NMR spectroscopy, and cleavage by aminopeptidase M. Biochemistry.1992; 31:11713–11720.CrossrefMedlineGoogle Scholar20 Gerszten RE, Chen J, Ishii M, Ishii K, Wang L, Nanevicz T, Turck CW, Vu T-HK, Coughlin SR. The thrombin receptor’s specificity for agonist peptide is defined by its extracellular surface. Nature.1994; 368:648–651.CrossrefMedlineGoogle Scholar21 Nanevicz T, Ishii M, Wang L, Chen M, Chen J, Turck CW, Cohen F, Coughlin SR. Mechanisms of thrombin receptor agonist specificity. J Biol Chem.1995; 270:21619–21625.CrossrefMedlineGoogle Scholar22 Nanevicz T, Wang L, Chen M, Ishii M, Coughlin SR. Activating mutations in the thrombin receptor’s agonist recognition domain: mutations in a G protein-coupled receptor’s extracellular domain cause transmembrane signaling. J Biol Chem.1996; 271:702–706.CrossrefMedlineGoogle Scholar23 Freedman NJ, Lefkowitz RJ. Desensitization of G protein-coupled receptors. Recent Prog Horm Res.1996; 51:319–351; discussion 352–353.MedlineGoogle Scholar24 Ishii K, Chen J, Ishii M, Koch WJ, Freedman NJ, Lefkowitz RJ, Coughlin SR. Inhibition of thrombin receptor signaling by a G protein-coupled receptor kinase: functional specificity among G protein-coupled receptor kinases. J Biol Chem.1994; 269:1125–1130.CrossrefMedlineGoogle Scholar25 Hoxie JA, Ahuja M, Belmonte E, Pizzaro S, Parton R, Brass LF. Internalization and recycling of activated thrombin receptors. J Biol Chem.1993; 268:13756–13763.CrossrefMedlineGoogle Scholar26 Ishii K, Hein L, Kobilka B, Coughlin SR. Kinetics of thrombin receptor cleavage on intact cells: relation to signaling. J Biol Chem.1993; 268:9780–9786.CrossrefMedlineGoogle Scholar27 Hein L, Ishii K, Coughlin SR, Kobilka BK. Intracellular targeting and trafficking of thrombin receptors: a novel mechanism for resensitization of a G protein-coupled receptor. J Biol Chem.1994; 269:27719–27726.CrossrefMedlineGoogle Scholar28 Shapiro MJ, Trejo J, Zeng DW, Coughlin SR. Role of the thrombin receptor’s cytoplasmic tail in intracellular trafficking: distinct determinants for agonist-triggered versus tonic internalization and intracellular localization. J Biol Chem.1996; 271:32874–32880.CrossrefMedlineGoogle Scholar29 Woolkalis MJ, DeMelfi TJ, Blanchard N, Hoxie JA, Brass LF. Regulation of thrombin receptors on human umbilical vein endothelial cells. J Biol Chem.1995; 270:9868–9875.CrossrefMedlineGoogle Scholar30 Connolly AJ, Ishihara H, Kahn ML, Farese RV, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature.1996; 381:516–519.CrossrefMedlineGoogle Scholar31 Darrow AL, Fung LW, Ye RD, Santulli RJ, Cheung WM, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan CM, Peterson PA, Andrade GP. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost.1996; 76:860–866.CrossrefMedlineGoogle Scholar32 Rugh R. The Mouse: Its Reproduction and Development. Oxford, England: Oxford University Press; 1990:265.Google Scholar33 Shivdasani RA, Rosenblatt MF, Zucker FD, Jackson CW, Hunt P, Saris CJ, Orkin SH. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell.1995; 81:695–704.CrossrefMedlineGoogle Scholar34 Cui J, O’Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature.1996; 384:66–68.CrossrefMedlineGoogle Scholar35 Connolly TM, Condra C, Feng DM, Cook JJ, Stranieri MT, Reilly CF, Nutt RF, Gould RJ. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost.1994; 72:627–633.CrossrefMedlineGoogle Scholar36 Derian CK, Santulli RJ, Tomko KA, Haertlein BJ, Andrade-Gordon P. Species differences in platelet responses to thrombin and SFLLRN: receptor-mediated calcium mobilization and aggregation and regulation by protein kinases. Thromb. Res.1995; 6:505–519.Google Scholar37 Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature.1997; 386:502–506.CrossrefMedlineGoogle Scholar38 Ishihara H, Zeng D, Connolly AJ, Tam C, Coughlin SR. Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. Blood. In press.Google Scholar39 Hung DT, Vu T-KH, Wheaton VI, Ishii K, Coughlin SR. The cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation: blocking antiserum to the thrombin receptor’s hirudin-like domain. J Clin Invest.1992; 89:1350–1353.CrossrefMedlineGoogle Scholar40 Molino M, Bainton DF, Coughlin SR, Brass LF. Thrombin receptors on human platelets: initial localization and subsequent redistribution during platelet activation. J Biol Chem.1996; 272:6011–6017.Google Scholar41 Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential novel proteinase activated receptor. Proc Natl Acad Sci U S A.1994; 91:9208–9212.CrossrefMedlineGoogle Scholar42 Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Wool
Referência(s)